List of ANSES toxicity reference values (TRVs)
The Agency entrusted TRV validation to the Expert Committee (CES) on "Health reference values ". Accordingly, toxicity reference values have already been established for the following substances (substances or mixtures).
> See our article on toxicity reference values (TRVs)
Chemical | Publication year | Sort of TRV | TRV | Internal TRV | |
Substances | |||||
2009 | Carcinogen TRV Inhalation route |
3,4.10-3 (mg.m-3)-1
| / | ||
2022 | Chronic TRV Inhalation route | 2 µg.m-3 | / | ||
Carcinogen TRV Inhalation route | 2,43.10-7 (µg.m-3)-1 | / | |||
2018 | Acute TRV Oral route | 73 µg.kg p.c.-1.d-1 | / | ||
2018 | Acute TRV Inhalation route | 256 µg.m-3 | |||
2018 | Subchronic TRV Oral route | 16 µg.kg p.c.-1.d-1 | |||
2018 | Subchronic TRV Inhalation route | 55 µg.m-3 | |||
2018 | Chronic TRV Oral route | 5 µg.kg p.c.-1.d-1 | |||
2018 | Chronic TRV Inhalation route | 18 µg.m-3 | |||
2009 | Chronic TRV Inhalation route | 0,07 mg.m-3 | / | ||
2018 | Acute TRV Oral route | 11 µg.kg p.c.-1.d-1 | / | ||
2018 | Acute TRV Inhalation route | 39 µg.m-3 | |||
2018 | Subchronic TRV Oral route | 5 µg.kg p.c.-1.d-1 | |||
2018 | Subchronic TRV Inhalation route | 18 µg.m-3 | |||
2018 | Chronic TRV Oral route | 1 µg.kg p.c.-1.d-1 | |||
2018 | Chronic TRV Inhalation route | 4 µg.m-3 | |||
2018 | Subchronic TRV Oral route | 5 µg.kg p.c.-1.d-1 | / | ||
2018 | Subchronic TRV Inhalation route | 18µg.m-3 | |||
2018 | Chronic TRV Oral route | 1 µg.kg p.c.-1.d-1 | |||
2018 | Chronic TRV Inhalation route | 4 µg.m-3 | |||
2015 | Chronic TRV Oral route | 0,32 mg .kg.pc-1.d-1 | / | ||
2015 | Chronic TRV Inhalation route | 2,7 mg.m-3 | |||
2015 | Carcinogen TRV Oral route | 1,3.10-5 (µg.kg p.c.-1.d-1)-1 | |||
2015 | Carcinogen TRV Inhalation route | 3,8.10-6 (µg.m-3)-1 | |||
(in French only) | 2022 | Acute TRV Inhalation route | 6,9 µg.m-3 | / | |
Subchronic TRV Inhalation route | 0,44 µg.m-3 | ||||
Chronic TRV Inhalation route | 0,2 µg.m-3 | ||||
Carcinogen TRV Inhalation route | No TRV | ||||
2017 | Acute TRV Inhalation route | 5,9 mg.m-3 | / | ||
Subchronic TRV Inhalation route | 0,5 mg.m-3 | ||||
Chronic TRV Inhalation route | 0,5 mg.m-3 | ||||
2013 | Carcinogen TRV Inhalation route | 2,6.10-5 (µg.m-3)-1 | / | ||
2012 | Chronic TRV Oral route | 0,05 mg.kg-1.d-1 | / | ||
2008 | Subchronic TRV Oral route | 0,5 mg.kg-1.d-1 | / | ||
Cadmium and cadmium compounds (CAS 7440-43-9, 10108-6-2, 1306-19-0, 10124-36-4, 1306-23-6, 10325-94-7) | (in French) | Chronic TRV Oral route | 0,35 µg.kg-1.d-1 | 0,5 µg/g creat | |
Chronic TRV Inhalation route
| 0,45 µg.m-3 | ||||
Carcinogen TRV Inhalation route
| 0,3 µg.m-3 | ||||
2017 | Carcinogen TRV Inhalation route | 0,11 mg.m-3 | / | ||
2010 | Chronic TRV Oral route | 28 µg.kg-1.d-1 | / | ||
(in French) | 2021 | Chronic TRV Oral route | 0,17 µg.kg-1.d-1 | 0,40 µg/L plasma | |
2008 | Chronic TRV Inhalation route | 63 µg.m-3 | / | ||
2019 | Subchronic TRV Oral route | 0,14 µg.kg-1.d-1 | / | ||
(CAS 541-02-6) | 2017 | Chronic TRV | 6,4 mg.m-3 | / | |
2010 | Chronic TRV Oral route | 30 µg.kg-1.d-1 | / | ||
2008 | Subchronic TRV Oral route | 0,002 mg.kg-1.d-1 | / | ||
2015 | Chronic TRV Oral route | 0,8 mg.kg pc-1.d-1 | / | ||
2015 | Chronic TRV Inhalation route | 3 mg.m-3 | |||
| 2015 | Chronic TRV Oral route | 4 mg.kg pc-1.d-1 | / | |
2015 | Chronic TRV Inhalation route | 14,5 mg.m-3 | |||
2015 | Developmental TRV Oral route | 2 mg.kg pc-1.d-1 | |||
2015 | Developmental TRV Inhalation | 7,2 mg.m-3 | |||
2015 | Carcinogen TRV Oral route | 7,8.10-6 (µg.kg p.c.-1.d-1)-1 | |||
2015 | Carcinogen TRV Inhalation route | 2,2.10-6 (µg.m-3)-1 | |||
2009 | Acute TRV Oral route | 260 µg.kg-1.d-1 | / | ||
Chronic TRV Oral route | 840 µg.kg-1.d-1 | ||||
2017 | Acute TRV (reprotoxic) Oral route | 0,002 mg.kg-1.d-1 | / | ||
2017 | Acute TRV (reprotoxic) Oral route | 0,004 mg.kg-1.d-1 | / | ||
Dimethyl phthalate (CAS 131-22-3) | 2015 |
| No TRV | / | |
2017 |
| No TRV | / | ||
2015 | Chronic TRV Inhalation route | 6,4 mg.m-3 | / | ||
2016 | Acute TRV Inhalation route | 22 mg.m-3 | / | ||
Subchronic TRV Inhalation route | 4,3 mg.m-3 | ||||
Chronic TRV Inhalation route | 1,5 mg.m-3 | ||||
2017 | Acute TRV Inhalation route | 123 µg.m-3 | / | ||
Chronic TRV Inhalation route | 123 µg.m-3 | ||||
2012 | Blood lead level |
| 15 µg.L-1 blood | ||
2008 | Subchronic TRV Oral route | 0,05 mg.kg-1.d-1 | / | ||
| 2017 | Chronic TRV Inhalation route | 0,7 mg.m-3 | / | |
| 2019 | Subchronic TRV Oral route | 1 ng.kg-1.d-1 | / | |
2017 | Chronic TRV Inhalation route | 2 mg.m-3 | / | ||
2013 | Chronic TRV Inhalation route | 3 mg.m-3 | / | ||
2009 | Carcinogen TRV Inhalation and oral route | No TRV | / | ||
N-nitrosomorpholine (CAS 59-89-2) | 2012 | Carcinogen TRV Oral route | 4 (mg.kg p.c.-1.d-1)-1 | / | |
2013 | Chronic TRV Inhalation route | 37 µg.m-3 | / | ||
Carcinogen TRV
Inhalation route | 5,6.10-3 (mg.m-3)-1 | ||||
2009 | Chronic route Oral route | 80 µg.kg-1.d-1 | / | ||
2009 | Carcinogen TRV Oral route | 6.10-5 (µg.kg-1.d-1)-1 | |||
2009 | Chronic TRV Oral route | 34 µg.kg-1.d-1 | / | ||
2009 | Carcinogen TRV Oral route | 5.10-5 (µg.kg-1.d-1)-1 | |||
2009 | Subchronic TRV Oral route | 0,03 mg.kg-1.d-1 | / | ||
2009 | Subchronic TRV Oral route | 0,03 mg.kg-1.d-1 | / | ||
2017 | Chronic TRV Inhalation route | 183 mg.m-3 | / | ||
2022 | Chronic TRV Oral route | 1.5 µg.kg-1.d-1 | / | ||
2018 | Acute TRV Inhalation route | 1,38 mg.m-3 | / | ||
Subchronic TRV Inhalation route | 0,4 mg.m-3 | ||||
Chronic TRV Inhalation route | 0,4 mg.m-3 | ||||
Carcinogen TRV Inhalation route | 2,6.10-7 (µg.m-3)-1
| ||||
2017 | Chronic TRV Oral route | 0,08 mg.kg-1.d-1 | / | ||
2017 | Chronic TRV Oral route | 0,32 mg.kg-1.d-1 | / | ||
(in French only)
| 2019 | Provisional acute TRV Oral route | 0.13 µg.kg pc-1.j-1 | / | |
2020 | Acute TRV Oral route | 0,1 µg.kg-1.j-1 | / | ||
2015 | No TRV | / | |||
2015 | TRV toxic to reproduction Oral route | 1,9 mg.kg pc-1.d-1 | / | ||
2015 | Chronic TRV Oral route | 0,6 mg.kg pc-1.d-1 | |||
2015 | Chronic TRV Inhalation route | 2,1 mg.m-3 | |||
2019 | Chronic TRV Inhalation | 0,12 µg.m-3 | / | ||
2009 | Acute TRV Oral route | 300 µg.kg-1.d-1 | / | ||
2018 |
Acute TRV Inhalation route | No TRV | / | ||
2018 |
Subchronic TRV Inhalation route | 3,2mg.m-3 | |||
2018 |
Chronic TRV Inhalation route | 3,2 mg.m-3 | |||
2018 | Carcinogen TRV Inhalation route | 10-6 (µg.m-3)-1 | |||
2017
| Acute TRV Inhalation route | 21 mg.m-3 | / | ||
Chronic TRV Inhalation route | 19 mg.m-3 | ||||
2012 | Carcinogen TRV Oral route | 0,625 (mg.kg-1.d-1)-1 | / | ||
2012 | Carcinogen TRV Inhalation route | 0,0038 (mg.m-3)-1 | |||
(in French) | 2021 | Reprotoxic TRV Oral route | 0,08 mg.kg-1.d-1 | / | |
Reprotoxic TRV Inhalation route | 0,26 mg.m-3 | ||||
Chronic TRV Oral route | 0,03 mg.kg-1.d-1 | ||||
Chronic TRV Inhalation route | 0,12 mg.m-3 | ||||
2020 | Acute TRV Inhalation route | 8,7 mg.m-3 | / | ||
2020 | Chronic TRV Inhalation route | 0,1 mg.m-3 |